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A genome-wide linkage and association scan reveals
novel loci for autism
Lauren A. Weiss1,2*{, Dan E. Arking3* & The Gene Discovery Project of Johns Hopkins & the Autism Consortium{
Although autism is a highly heritable neurodevelopmental dis-
order, attempts to identify specific susceptibility genes have thus
far met with limited success1. Genome-wide association studies
using half a million or more markers, particularly those with very
large sample sizes achieved through meta-analysis, have shown
great success in mapping genes for other complex genetic traits.
Consequently,we initiated a linkage and associationmapping study
using half amillion genome-wide single nucleotide polymorphisms
(SNPs) in a common set of 1,031 multiplex autism families (1,553
affected offspring). We identified regions of suggestive and signifi-
cant linkage on chromosomes 6q27 and 20p13, respectively. Initial
analysis did not yield genome-wide significant associations;
however, genotyping of top hits in additional families revealed an
SNP on chromosome 5p15 (between SEMA5A and TAS2R1) that
was significantly associated with autism (P5 23 1027). We also
demonstrated that expression of SEMA5A is reduced in brains from
autistic patients, further implicating SEMA5A as an autism suscep-
tibility gene. The linkage regions reported here provide targets for
rare variation screening whereas the discovery of a single novel
association demonstrates the action of common variants.
For a high-resolution genetic study of autism, we selected families
with multiple affected individuals (multiplex) from the widely
studied Autism Genetic Resource Exchange (AGRE) and US
National Institute for Mental Health (NIMH) repositories (Sup-
plementary Methods and Supplementary Table 1). Although the
phenotypic heterogeneity in autism spectrum disorders (ASDs) is
extensive, in our primary screen we selected families in which at least
one proband met Autism Diagnostic Interview-Revised (ADI-R) cri-
teria for diagnosis of autism and included additional siblings in the
same nuclear family affected with any autism spectrum disorder. We
previously reported an early copy number analysis that revealed a
significant role for microdeletion and duplication of 16p11.2 in ASD
causation2; here, we present extensive genome-wide linkage and asso-
ciation analyses performed with this high density of SNPs and
identify independent and novel genome-wide significant results by
both linkage and association analyses.
Wecombined families and samples fromtwosources for theprimary
genetic association screen. The AGRE sample included nearly 3,000
individuals from over 780 multiplex autism families in the AGRE
collection3 genotyped at the Broad Institute on the Affymetrix 5.0
platform, which includes over 500,000 SNPs. The NIMH sample
included a total of 1,233 individuals from 341 multiplex nuclear
families (258 of which were independent of the AGRE sample) geno-
typed at the Johns Hopkins Center for Complex Disease Genomics on
Affymetrix 5.0 and500Kplatforms, including the same SNPmarkers as
were genotyped in the AGRE sample.
Beforemerging,we carefully filtered eachdata set separately to ensure
the highest possible genotype quality for analysis, because technical
genotyping artefacts can create false positive findings. We therefore
examined the distribution of x2 values for the highest quality data,
and used a series of quality control (QC) filters designed to identify a
robust set of SNPs, including data completeness for each SNP,
Mendelian errors per SNP and per family, and a careful evaluation of
inflation of association statistics as a function of allele frequency and
missing data (seeMethods). As 324 individuals were genotyped at both
centres, we performed a concordance check to validate our approach.
After excluding one sample mix-up, we obtained an overall genotype
concordance between the two centres of 99.7% for samples typed on
500K at Johns Hopkins University and 5.0 at the Broad Institute and
99.9%for samples runon5.0 arrays at both sites.The combineddata set,
consisting of 1,031 nuclear families (856with twoparents) and a total of
1,553 affected offspring, was used for genetic analyses (Supplementary
Table 1). These data were publicly released in October 2007 and are
directly available from AGRE and NIMH.
For linkage analyses, the commonAGRE/NIMHdata setwas further
merged with Illumina 550K genotype data generated at the Children’s
Hospital of Philadelphia (CHOP) and available from AGRE, adding
,300 nuclear families (1,499 samples). We used the extensive overlap
of samples between the AGRE/NIMH and the CHOP data sets (2,282
samples) to select an extremely high quality set of SNPs for linkage
analysis. Specifically, we only included SNPs genotyped in both data
sets with.99.5% concordance and#1 Mendelian error.
Linkage analysis involving high densities of markers, where clusters
of markers are in linkage disequilibrium (LD), can falsely inflate the
evidence for genetic sharing among siblings when neither parent is
genotyped4. To alleviate these concerns, we analysed a pruned set of
16,311 highly polymorphic, high-quality autosomal SNPs which were
filtered to remove any instances in which two nearby markers were
correlated with r2. 0.1, providing a marker density of,0.25 cM (see
Methods). In this analysis of 878 families, four genomic regions
showed LOD scores in excess of 2.0 and one region, 20p13, exceeded
the formal genome-wide significance threshold of 3.6 (ref. 5) (maxi-
mum LOD, 3.81; Fig. 1a and Supplementary Table 2). Restricting
analysis to only those families with both parents genotyped (784
families) showed that these results are not an artefact of missing
parental data (Fig. 1b). We further tested the stability of these results
by varying the recombination map and halving the marker density by
placing every other marker into two non-overlapping SNP sets
(Methods Summary); all analyses showed consistent and strong link-
age to the same regions (data not shown).
Weused the transmission disequilibrium test (TDT) across all SNPs
passing quality control in the complete family data set for association
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analyses as the TDT is not biased by population stratification. We
estimated a threshold for genome-wide significance using both per-
mutation (P, 2.53 1027) and estimating the effectivenumber of tests
(P, 3.43 1027), and use the more conservative here (see Methods).
No SNP met criteria for genome-wide significance at P, 2.53 1027.
However, we observed an excess of independent regions associated at
P, 1025 (6 observed versus 1 expected) and P, 1024 (30 observed
versus 15 expected) despite the lack of overall statistical inflation
(l5 1.03, Supplementary Fig. 1), suggesting that common variants
in autism exist, but that our initial scan did not have sufficient statis-
tical power to identify them definitively (Table 1 and Supplementary
Fig. 2).
For the TDT associations with P, 1024, we additionally used the
cases thatwere excluded fromtheTDTdue tomissingparental data.We
matched 90 independent and unrelated cases with 1,476NIMHcontrol
samples genotyped on the Affymetrix 500K arrays6, and performed
case-control association analysis (Supplementary Table 3), combining
these results with the TDT data. Promisingly, we now observed eight
SNPs (in seven independent regions) with association at P, 1025
(Table 1). Of note, comparing Caucasian with non-Caucasian samples
in the AGRE/NIMH data set, we did not observe significant heteroge-
neity for top results.
Our strongest associations were at chromosome 4q13 (rs17088254,
P5 8.53 1026) between CENPC1, a centromere autoantigen, and
EPHA5, an ephrin receptor potentially involved in neurodevelop-
ment; at 5p15 (rs10513025, P5 1.73 1026) in the EST DB512398,
located between SEMA5A and TAS2R1; at 6p23 (rs7766973,
P5 6.83 1027) in JARID2, an orthologue of themouse jumonji gene,
encoding a nuclear protein essential for embryogenesis, especially
neural tube formation; at 9p24 (rs4742409, P5 7.93 1026) between
PTPRD, a protein tyrosine phosphatase involved in neurite out-
growth, and JMJD2C (also called KDM4C), a jumonji-domain con-
taining protein involved in tri-methyl-specific demethylation; at 9q21
(rs952834, P5 7.83 1026) between ZCCHC6, a zinc finger and
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Figure 1 | Genome-wide linkage results. a, The genome-wide linkage results
are shown, with the orange line indicating non-parametric linkage (NPL)
LOD5 3 and the yellow line indicating NPL LOD5 2. b, Four
chromosomes with LOD. 2. The black and blue lines indicate results from
families with both parents genotyped and all families, respectively. The green
line indicates information content (right-hand y axis). The red circle
indicates the position of the centromere.
Table 1 | Top TDT results and replication data
Locus Scan Replication Meta-analysis
Chromosome Position SNP LD, proxy T U OR P P (with
case-control)
T U OR P (1-sided) P (meta) P (proxy)
4 68019960 rs17088254 – 137 219 0.63 1.43 1025 8.53 1026 48 38 1.3 NA 0.011 4.83 1023
4 68189460 rs2632453 r2 50.67,
rs17088254
171 245 0.70 2.93 1024 2.43 1024 248 234 1.06 NA 0.022 –
5 9676622 rs10513025 – 84 152 0.55 9.63 1026 1.73 1026 152 199 0.76 6.13 1023 2.13 1027 –
6 15365718 rs13208655 r2 50.74,
rs7766973
NA NA NA NA NA 829 831 1.00 0.48 0.48 –
6 15376030 rs7766973 – 631 811 0.78 2.13 1026 6.83 1027 139 142 0.98 0.43 2.03 1024 2.83 1024
9 7763723 rs4742408 – 591 739 0.80 4.93 1025 2.73 1024 241 224 1.08 NA 0.030
9 7764180 rs4742409 – 499 645 0.77 1.63 1025 7.93 1026 77 87 0.89 0.22 1.63 1024 3.6 3 1024
9 7764774 rs6477233 r250.6,
rs4742409
NA NA NA NA NA 734 752 0.98 0.32 0.32 –
9 86471331 rs952834 – 656 825 0.80 1.13 1025 7.83 1026 173 160 1.08 NA 5.43 1023 –
10 68842909 rs7923367 – 89 160 0.56 6.83 1026 3.43 1026 18 25 0.72 0.14 4.13 1025 –
11 22775950 rs12293188 – 449 327 1.37 1.23 1025 1.13 1026 486 513 0.95 NA 3.03 1023 –
11 22785182 rs16910190 – 421 308 1.37 2.83 1025 1.43 1025 55 67 0.82 NA 0.014 –
11 22785488 rs16910194 – 444 330 1.35 4.23 1025 3.73 1026 80 75 1.07 0.34 2.83 1024 –
11 22791645 rs3763947 – 429 320 1.34 6.83 1025 3.43 1025 57 57 1.00 NA 2.43 1023 –
Top results from the combined TDT and case-control analysis are shown (P, 1025), with replication data, where it exists. For Sequenom genotyping that used a proxy SNP, that SNP and its LD (r2)
with the SNP of interest is shown. Transmitted (T) and untransmitted (U) counts and odds ratios (OR) for the minor allele are shown for each SNP. Replication results are shown for additional autism
family data using Affymetrix and Sequenom genotyping technology. The meta-analysis P-value is shown as is the P-value for meta-analysis where proxy SNP data was included. Bold font: P, 1025
TDT/case-control analysis, P,0.05 replication, P, 2.5 3 1027 meta-analysis. NA, not applicable.
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CCHC domain containing protein, and GAS1, growth-arrest-specific
protein; at 10q21 (rs7923367, P5 3.43 1026) in CTNNA3, a3 cate-
nin, which may be involved in the formation of stretch-resistant cell–
cell adhesion complexes; and two SNPs on 11p14 (rs12293188,
P5 1.13 1026; rs16910194, P5 3.7 3 1026) in GAS2, a caspase-3
substrate that has a role in regulating microfilament and cell shape
changes during apoptosis and can modulate cell susceptibility to
p53-dependent apoptosis by inhibiting calpain activity (Table 1).
To confirm whether any of these top results might indicate true
susceptibility loci, we attempted to replicate these signals, as well as
others with P, 1024 in the initial TDT thatmet stringent genotyping
quality criteria (Supplementary Table 3). We used several data
sources to replicate the association results. First, we used additional
autism family samples (318 trios collected by investigators of the
Autism Consortium and in Montreal) with genome-wide
Affymetrix 5.0/500K array data also genotyped at the Genetic
Analysis Platform of the Broad Institute using the same conditions,
QC and analysis pipelines (Methods).
Second, independent Autism Genome Project (AGP) families,
along with a set of Finnish families and a set of Iranian trios, were
used for replication of our top findings (n5 1,755 trios). Two
Sequenom replication pools were designed, attempting to include as
many of the regions associated at P, 1024 as possible. The full set of
SNPs considered and those successfully genotyped are shown in
Supplementary Table 3, with linkage disequilibrium (r2) noted for
SNPs selected as proxies for Affymetrix markers. One of the eight
SNPs with P, 1025 (rs10513025) that failed in this Sequenom assay
was subsequently replaced in a subset of AGP samples with a TaqMan
assay. This assay showed 99.89% concordance with Affymetrix geno-
types in the overlapping AGRE-NIMH samples (2,797 out of 2,800
concordant genotypes), with manual review of the Affymetrix geno-
type calls also confirming the marker to be of extremely high quality
(Supplementary Fig. 4). In the independent replication effort, only
rs10513025 was associated with P, 0.01 (Table 1).
Combining the scan and replication data, only rs10513025 met cri-
teria for genome-wide significance defined by LD and permutation
analyses (P, 2.53 1027). To increase coverage of this region and fill
inmissing genotypes and SNPs that failed quality control, weperformed
imputation analysis. rs10513026 was highly (but not perfectly) corre-
lated to the replicated chromosome 5 SNP (rs10513025) and showed
even stronger association than originally observed with rs10513025
(Supplementary Fig. 3). These and several other promising SNPs were
directly genotyped in the original scan samples and, in fact, showed
higher levels of significance (Table 2). Direct genotyping confirmed that
rs10513026 showed stronger association than rs10513025 (P-value
4.53 1026 versus 9.83 1026 in the re-genotyped scan trios), increasing
the significance of this observation further. Several other promising
results from this analysis were genotyped in a subset of scan samples,
and, of note, the top SNP in imputation analysis (rs10874241, imputa-
tion P5 9.83 1027, odds ratio (OR)5 0.43) showed consistent results
(OR5 0.4, P5 43 1027) when directly genotyped (Supplementary
Table 4).
rs10513025 and neighbours are on chromosome 5p15 in a region
of LD containing several other ESTs and TAS2R1, a bitter taste recep-
tor (Supplementary Fig. 3). The SNPs are,80 kb upstream of sema-
phorin 5A (SEMA5A), a gene implicated in axonal guidance and
known to be downregulated in lymphoblastoid cell lines of autism
cases versus healthy controls7. An independent study at Children’s
Hospital Boston using whole blood (S.W.K., L.K. and Z.K., manu-
script in preparation) confirms this lower expression (P5 0.0034) of
SEMA5A in autism cases versus controls. To evaluate the role of this
locus in autism pathogenesis more completely, we evaluated the
entirety of 5p15 for copy-number variation. Despite excellent probe
coverage throughout the locus, no common or rare copy number
variants were detected in the entire AGRE scan in the region of LD
surrounding the associated SNPs and the entire SEMA5A locus
including 250 kb up- and downstream (see Methods).
To test directly SEMA5A expression in brains from autistic
patients, tissue samples from 20 cases with a primary diagnosis of
autism and 10 controls were obtained through the Autism Tissue
Program and the Harvard Brain Bank. Samples were dissected from
Brodmann area 19 of the occipital lobe cortex, a region demonstrat-
ing differences between autism cases and controls in functional
imaging studies, and subjected to quantitative PCR8. SEMA5A
expression, determined relative toMAP2 (neuron specific), was sig-
nificantly lower in autism brains than controls after adjustment for
the age at brain acquisition, post-mortem interval and sex
(P5 0.024, Fig. 2).
We also analysed our data for association signals at candidate
genes or regions with previous evidence of involvement in autism.
Although there are few well-replicated associations of biological can-
didate genes, there are many rare genetic variants, diseases and syn-
dromes associated with autism. Most of these loci have not been
systematically assessed to see whether common variation in the gene
or region might contribute to autism. We assessed four categories of
candidate loci: (1) genes with previous evidence for association with
common variation; (2) genes implicated by rare variants leading to
autism; (3) genes causingMendelian diseases associated with autism;
and (4) regions wheremicrodeletion ormicroduplication syndromes
are associated with autism. For each gene, we included all SNPs
passing basic quality criteria within 2 kb of the transcript.
Overall, therewere no compelling results in these sets (allP. 1024),
considering the number of SNPs tested, and only two regions met
criteria for region-wide (only SNPs in that gene/region considered)
or set-wide (for example, all candidate regions in the set of common
variant genes considered) significance by permutation testing
(Supplementary Table 5). MECP2 (Rett syndrome) met criteria for
region-wide association (P5 0.0071, 5 SNPs, Supplementary Table
5). Moreover, the Williams syndrome region was borderline for set-
wide significance (P5 0.051, Supplementary Table 5). One SNP in
particular showed strong association (rs2267831, P5 0.00012,
OR5 0.56)—as this was a rare SNP with undertransmission of the
minor allele, we genotyped a subset of families and observed similar,
slightly less significant distortion (OR5 0.61). The SNP is located
within GTF2IRD1, a transcription factor within the critical region
for the Williams syndrome cognitive behavioural profile9–11.
Table 2 | Chromosome 5p15 SNPs
SNP Chromosome Position MAF OR P Replication P
rs10513025 5 9676622 0.041 0.5526 9.583 1026 0.006059
rs10513026 5 9677106 0.040 0.53 4.503 1026 NA
rs16883317 5 9701592 0.038 0.53 7.203 1025 NA
Three SNPs in the chromosome 5p15 association locus genotyped by Sequenom iPLEX are
shown, with minor allele frequency (MAF), odds ratio (OR) and P-value in the AGRE and NIMH
sample, as well as replication data from all available samples for rs10513025 (see Methods).
NA, not applicable.
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Figure 2 | SEMA5A expression in autism brains. SEMA5A gene expression
is shown relative to MAP2. Diamonds indicate individual expression levels
for each sample; error bars indicate standard error (s.e.).
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There seems to be little overlap between the regions of strongest
linkage and association in this study. A more detailed assessment of
SNP and haplotype association in themost significant linkage regions
did not yield common variation that could explain the evidence for
linkage (Supplementary Table 6). This is an expected outcome if
linkage signals arise from rare, high penetrance variation (for which
the genotyping arrays do not offer an adequate proxy) whereas asso-
ciation is sensitive to common variation with lower penetrance (that
cannot be detected by linkage). For example, a 0.3% variant that
increases risk by tenfold would readily be picked up by this informa-
tive linkage scan, but would very likely not be assessed by the
common SNPs on the Affymetrix 5.0 array; by contrast, the modest
and protective impact of the 5% variant at the SEMA5A rs10513025
creates no detectable excess allele sharing among siblings but is
strongly detected by association.
During review of this manuscript, another genome-wide asso-
ciation study (GWAS) was published which identified significant
association to SNPs on chromosome 5p1412. Although there was sig-
nificant overlap between study samples, each of these scans contained
a large set of unique families, so we sought to evaluate independent
evidence of the top SNP (rs4307059) reported at 5p14. This SNP
happens to be directly genotyped by both Affymetrix and Illumina
platforms. We have a sizable number (n5 796) of affected subjects
with two parents genotyped (and of predominantly similar European
background). However, we observed no support for association at
this locus (T:U 354:335 in favour of the minor allele, a trend in the
opposite direction as reported).
Autism genes have been difficult to identify, despite the high herit-
abilityof autismspectrumdisorders.Up to10%ofautismcasesmaybe
due to rare sequence and gene dosage variants, for example,mutations
in NRXN1, NLGN3/NLGN4, SHANK3 and copy number variants at
15q11-q13 and 16p11.2. A number of diseases of known aetiology,
including Rett syndrome, fragile X syndrome, neurofibromatosis type
I, tuberous sclerosis, Potocki–Lupski syndrome, and Smith–Lemli–
Opitz syndrome are also associated with autism1,13. However, the
remaining 90% of autism spectrum disorders, although highly
familial, have unknown genetic aetiology. A genome-wide linkage
study using the Affymetrix 10K SNP array to genotype over 1,000
families found no genome-wide significant linkage signals, but docu-
mented suggestive linkage at 11p12-p13 and 15q23-q25 and rein-
forced a modest role for rare copy-number variants14.
Many complex diseases have recently had great success with
GWAS approaches, but most identified modest effects with odds
ratios less than 1.3 (http://www.genome.gov/26525384). Our asso-
ciation analysis has excellent statistical power (.80%) to find effects
of relatively common alleles (0.01–0.25 in frequency) explaining 1%
of the variance in autism at the genome-wide significant level. It is
near-perfectly powered for alleles of SNPs present on the array (or
perfectly proxied) down to 1% at the replication cutoff P, 1024,
assuming additive background genetic variance of 0.8 and shared
environmental variance of 0.05 with prevalence of 0.006. One of
the advantages of a family-based association test is that we avoid false
positive results generated by population stratification, and in addi-
tion, we have performed careful quality control to reduce the chances
of being misled by technical artefacts. However, the SNP coverage of
the Affymetrix 5.0 chips is incomplete; in fact, a recent re-sequencing
survey suggests that these arrays assay only 57% of variants with
minor allele frequency (MAF).5% at r25 0.8 (ref. 15).We therefore
cannot exclude untested variation of large effect in autism. The link-
age analysis, assuming a fully informative marker in 800 sibling pairs,
should detect sibling allele sharing of at least 55.125%16.
Our linkage analysis revealed two novel regions of linkage, 6q27
(LOD5 2.94) and 20p13 (LOD5 3.81), with the latter formally
exceeding the threshold for genome-wide significance. There is some
overlap between the more modest signals (LOD.2 on chromosome
15 and chromosome 17) and previously reported suggestive linkage
signals, but little overlap with themost promising regions of common
SNPassociation. This suggests that the regions of the genome showing
linkage may harbour rare variation, potentially with allelic heteroge-
neity across families, which would require re-sequencing to uncover,
as has been demonstrated for the 7q35 region17–19. Interestingly, sev-
eral of these regions overlap with rare syndromes or genetic events
known to be strong risk factors for autism. For example, an autism
case with a translocation disrupting 15q25 has been reported, whereas
the 17p region overlaps the Smith–Magenis and Potocki–Lupski syn-
drome region.
The initial TDT analysis of this large multiplex autism data set did
not reveal any associations meeting criteria for genome-wide signifi-
cance, suggesting that there are notmany common loci of moderate to
large effect size even in a highly heritable disorder like autism.
Nevertheless, replication data in our study identified a novel locuswith
genome-wide significant evidence for association to autism. In addi-
tion, several other SNPs in the region show similarly strong association
(rs10513026, rs16883317). We ascertained a large replication sample
from independent family studies with a replication at P5 0.0061 and
meta-analysis showed this association (P5 2.123 1027) to meet cri-
teria for genome-wide association in our experiment. This region on
chromosome 5 harbours the gene encoding the bitter taste receptor,
TAS2R1, and several uncharacterized ESTs and is adjacent to SEMA5A,
a member of the semaphorin axonal guidance protein family, which
has shown downregulated expression in transformed B lymphocytes
from autism samples7. We have further extended this finding by
directly demonstrating lowered SEMA5A gene expression in autism
brain tissue. This is an attractive candidate gene given that its protein is
a bi-functional guidancemolecule, which is both attractive and inhibi-
tory for developing neurons. Interestingly, the SEMA5A receptor is
plexin B3, which also signals through the tyrosine kinaseMET, a previ-
ously reported autism susceptibility gene20,21.
Finally, we investigated whether different classes of genes or
regions—loci previously implicated by functional or positional can-
didate gene association studies, rare variants implicated in autism,
Mendelian disorder genes with association to autism, or regions of
copy number variation associated with autism—showed association
with common alleles included in ourmarker set. Although there were
several nominally significant associations, only the Williams syn-
drome region (one SNP in GTF2IRD1) was borderline statistically
significant (P5 0.051), after correcting for the microdeletion/
duplication syndrome regions tested. In the category of Mendelian
disorders associated with autism, MECP2, the gene for Rett syn-
drome, showed region-wide statistical significance. These results
raise the possibility that Rett and Williams syndrome genes may
contribute more generally to autism spectrum disorders. Although
the genes in which common variation has been reported to be asso-
ciated with autism do not show evidence for association, this cannot
be interpreted as failure to replicate previous results in all cases,
because much of the variation reported as associated is not captured
on the Affymetrix platform (for example, length polymorphisms,
microsatellites, untagged SNPs such as the promoter variant at
MET21). Instead, despite a high density ofmarkers, our results suggest
that we did not identify additional common variation with evidence
for association. Overall however, our results indicate that these pos-
tulated candidate regions, mostly based on rare events known to
cause autism, are not among the regions with common alleles having
the strongest risk effects for autism.
Interestingly, both our linkage and association analyses, from the
primary and replication analyses, suggest that low-frequency (,0.05)
minor alleles may be common in autism. Intriguingly, the linkage
studies reveal low-frequency susceptibility alleles whereas the asso-
ciation analyses have uncovered rare alleles with odds ratios less than
0.6 (the common alleles in the population associated with increased
risk for autism). This can occur when the ancestral allele, that was
previously neutral or beneficial, now has detrimental effects revealed
by an evolutionarily recent environment, or when a pleiotropic func-
tion of the allele is selectively advantageous, or when this variation is
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hitch-hiking on a shared haplotype with a distinct beneficial allele22.
However, it is worth noting that our study design of ascertaining
multiplex families is not well powered to identify loci under this
genetic model of common major alleles associated with autism sus-
ceptibility.
We report genome-wide significant linkage as well as an asso-
ciation of common genetic variation with autism. Our results will
require follow-up to identify the functional variation in the linkage
and association regions that we report here and to probe the func-
tions of the relatively unstudied transcripts implicated. These results
could provide completely novel insight into the biology and patho-
genesis of a common neurodevelopmental disorder.
METHODS SUMMARY
Samples and genotyping.Our primary samples are from the AGRE and NIMH
Repositories. Replication with Affymetrix technology included NIMH controls,
families collected by members of the Autism Consortium, and families ascer-
tained from Montreal. Replication with Sequenom technology included the
Autism Genome Project, Finnish, and Iranian subsets of Autism Consortium
investigator-collected families. Details of the ascertainment for each sample
collection, genotyping and quality control processes can be found in Methods.
Linkage and association analysis. The linkage analysis was conducted with a
pruned autosomal SNP set (see Methods for details of marker selection) and
chromosome X set (670 SNPs) using the cluster option inMERLIN/MINX (r2,
0.1)23, yielding 16,581 independent markers. We performed confirmatory ana-
lysis on non-overlapping data sets by selecting alternative SNPs.
Association analysis was performed in PLINK24. The basic association test was
a transmission disequilibrium test (TDT), and the extra cases versus controls
analysis was performed by allelic association, after excluding cases that were not
well matched to the controls, based on multi-dimensional scaling (l , 1.1).
Combining the TDT and case-control tests was performed using expected and
observed allele counts by the formula Zmeta5 (
P
exp2
P
obs)/!
P
var. Meta-
analysis of AGRE/NIMH and replication data was performed using the statistic
(ZAGRE/NIMH1Zreplication)/!2. Gene-set analysis was performed in PLINK using
the set-based TDT. Imputation-based association was performed in PLINKwith
the proxy-tdt command, using theHapMapCEUparent samples as the reference
panel and information score.0.8. Haplotype analysis in the linkage regions was
performed using 5-SNP sliding windows, as implemented in PLINK hap-tdt. See
Methods for details of determination of genome-wide significance thresholds.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
All samples used in this study arose from investigations approved by the indi-
vidual and respective Institutional Review Boards in the USA and at inter-
national sites where relevant. Informed consent was obtained for all adult
study participants; for children under age 18, both the consent of the parents
or guardians and the assent of the child were obtained.
Primary study samples: AGRE samples. The Autism Genetic Resource
Exchange (AGRE) curates a collection of DNA and phenotypic data frommulti-
plex families with autism spectrum disorder (ASD) available for genetic
research3. We genotyped individuals from 801 families, selecting those with at
least one child meeting criteria for autism by the Autism Diagnostic Interview-
Revised (ADI-R)25, whereas the second affected child had an AGRE classification
of autism, broad spectrum (patterns of impairment along the spectrum of per-
vasive developmental disorders, including pervasive developmental disorder not
otherwise specified (PDD-NOS) and Asperger’s syndrome) or not quite autism
(NQA, individuals who are no more than one point away from meeting autism
criteria on any or all of the social, communication, and/or behaviour domains
and meet criteria for ‘age of onset’; or, individuals who meet criteria on all
domains, but do not meet criteria for the ‘age of onset’). We excluded probands
with widely discrepant classifications of affection status via the ADI-R and
Autism Diagnostic Observation Schedule (ADOS) that could not be reconciled.
We also excluded families with known chromosomal abnormalities (where kar-
yotyping was available), and those with inconsistencies in genetic data (generat-
ing excess Mendelian segregation errors or showing genotyping failure on a test
panel of 24 SNPs used to check gender and sample identity with the full array
data). The self-reported race/ethnicity of these samples is 69% white, 12%
Hispanic/Latino, 10% unknown, 5% mixed, 2.5% each Asian and African
American, less than 1% native Hawaiian/Pacific Islander and American
Indian/native Alaskan.
Primary study samples: NIMH samples. The NIMHAutism Genetics Initiative
maintains a collection ofDNA frommultiplex and simplex familieswithASD.We
genotyped individuals from 341 nuclear families, 258 of which were independent
of the AGRE data set, with at least one child meeting criteria for autism by the
ADI-R, and a second child considered affected using the same criteria as described
for the AGRE data set above. Similar exclusion criteria were used, including
known chromosomal abnormalities and excess non-Mendelian inheritance.
The self-reported race/ethnicity of these samples is 83% white, 4% Hispanic,
2% unknown, 7% mixed, 3% Asian and 1% African American.
Primary study samples: merged data set for primary screening. We used the
Birdseed algorithm for genotype calling at both genotyping centres26,27. As 324
individuals were genotyped at both centres, we performed a concordance check.
One sample showed substantial differences between the two centres, but no
excess of Mendelian errors, indicating that a sample mix-up occurred in which
each centre genotyped a different sibling that was identified as the same sample.
Excluding this sample, overall genotype concordance between the two centres
was 99.72%.
Before merging data, we examined the distribution of chi-squared values and
used a series of quality control (QC) filters designed to identify a robust set of
SNPs.Wediscovered that filtering AGRE genotypes to 98%completeness and less
than 10 Mendelian errors (MEs) was sufficient to remove SNPs that artificially
inflated the chi-squareddistribution for SNPswithMAF. 0.05. ForMAF, 0.05,
we observed much greater inflation (l5 1.17), due entirely to a strong excess of
SNPs with under-transmission of the minor allele (OR, 1). Whereas the same
filters yielded high-quality results for SNPs with over-transmission of the minor
allele (l5 1.04), we found thatmuch stricter filtering was required for rarer SNPs
with OR, 1 (missing data ,0.005). This is not unexpected based on a well-
documented bias in the TDT: if missing data are preferentially biased against
heterozygotes or rare homozygotes, significant, artificial over-transmission of
the common allele is expected28,29. To achieve comparable quality for the
NIMH data set, we filtered on 96% completeness and fewer than 4 MEs. Our
finalQQplot for the combineddata set is shown inSupplementary Fig. 1 andhas a
l< 1.03, less than that observed in theWellcomeTrust Case Control Consortium
paper for five of the sevenphenotypes studied30. The combineddata set, consisting
of 1,031 families (856with two parents) and a total of 1,553 affected offspring, was
used for association testing.
For linkage analyses, the combined AGRE/NIMH data set was further merged
with Illumina 550K genotype data generated at the Children’s Hospital of
Philadelphia (CHOP) and available from AGRE, adding ,300 nuclear families
(1,499 samples). We used the extensive overlap of samples between the AGRE/
NIMH and the CHOP data sets (2,282 samples) to select an extremely high
quality set of SNPs for linkage analysis. Specifically, we required SNPs to be
on both the Affymetrix 500K/5.0 and Illumina 550K platforms, with .99.5%
concordance across platforms. We further restricted SNPs to MAF. 0.2, ,1%
missing data, Hardy–Weinberg P. 0.01, and no more than 1 ME. This left
,36,000 SNPs of outstanding quality. For autosomal SNPs, we further pruned
using PLINK to remove SNPs with r2. 0.1, yielding 16,311 SNPs.
Replication samples: NIMH control samples. Controls obtained from the
NIMH Genetics Repository were genotyped on the Affymetrix 500K platform
at the Broad Institute Genetic Analysis Platform for another study6. Of these,
1,494 matched well with our sample, and were used as controls to compare with
the cases and parents in our study.
Replication samples: Montreal samples. Subjects diagnosed with autism spec-
trumdisorders with both of their parents were recruited from clinics specializing
in the diagnosis of Pervasive Developmental Disorders (PDD), readaptation
centres, and specialized schools in the Montreal and Quebec City regions,
Canada, as described31. Subjects with ASD were diagnosed by child psychiatrists
and psychologists expert in the evaluation of ASD. Evaluation based on the
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria included
the use of the ADI-R25 and the ADOS32. As an additional screening tool for the
diagnosis of ASD, the Autism Screening Questionnaire, which is derived from
the ADI-R, was completed33. Furthermore, all proband medical charts were
reviewed by a child psychiatrist expert in PDD to confirm their diagnosis and
exclude subjects with any co-morbid disorders. Exclusion criteria were: (1) an
estimated mental age ,18 months; (2) a diagnosis of Rett syndrome or child-
hood disintegrative disorder; and (3) evidence of any psychiatric and neuro-
logical conditions including: birth anoxia, rubella during pregnancy, fragile X
syndrome, encephalitis, phenylketonuria, tuberous sclerosis, Tourette andWest
syndromes. Subjects with these conditions were excluded based on parental
interview and chart review. However, participants with a co-occurring diagnosis
of semantic-pragmatic disorder (owing to its large overlap with PDD), attention
deficit hyperactivity disorder (seen in a large number of patients with ASD
during development), and idiopathic epilepsy (related to the core syndrome of
ASD) were eligible for the study.
Replication samples: Santangelo EDSP family samples. Families were ascer-
tained for having one ormore autistic children and at least one non-autistic child
aged 16 or older for an extremely discordant sibling-pair linkage study.
Recruitment took place in Massachusetts and surrounding states through con-
tacts with parent support and patient advocacy groups, brochures, newsletters
and the study website. Parents were interviewed about their children, and non-
autistic children were interviewed about themselves. An informant/caregiver,
usually the proband’s mother, was interviewed using the ADI-R to confirm
the diagnosis of autism at age 4–5 years25,34. Families were included if the affected
children met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-
IV) criteria for autistic disorder and their non-autistic siblings (aged 16 and
older) did not display any of the broader autism phenotype traits, which were
assessed with the (M-PAS-R), the Pragmatic Language Scale (PLS), and the
Friendship Interview35,36. Probandswere excluded if they hadmedical conditions
associated with autism such as fragile X syndrome or gross CNS injury, or if they
were under 4 years of age, owing to the possible uncertainty in diagnosis at
younger ages. Twenty-nine families met eligibility criteria for the study and
comprised the final sample for analysis.
Replication samples: high functioning autism family samples. Families were
included if their affected child had been previously diagnosed with Autism or
Asperger’s syndrome, had a level of intellectual functioning above the range of
mental retardation (that is, full scale, verbal and performance IQ. 70), chro-
nological age between 6 and 21 years, and an absence of significant medical or
neurological disorders (including fragile X syndrome and tuberous sclerosis).
Families were ascertained and recruited through the Acute Residential
Treatment (ART) programmes and outpatient child and adolescent services at
McLean Hospital, as well as through associated hospitals and clinics. Brochures
and a website were also used. Thirty-three families (133 participants) were
enrolled in the study. Participation was voluntary.
Replication samples:MGH–Finnish collaborative samples.Altogether 58 indi-
viduals with a diagnosis of high functioning autism (HFA) or Asperger’s syn-
drome were recruited in Finland. Fifty-two children and adolescents aged
8–15 years were identified from patient records at the Oulu University
Hospital in 2003. These children and adolescents have been evaluated for
HFA/Asperger’s syndrome at the Oulu University Hospital. In addition, six
children (3 boys, 3 girls) 11 years of age were recruited from an epidemiological
study conducted in 2001 (ref. 37).
All participants had full-scale IQ scores greater than or equal to 80 measured
with theWechsler Intelligence Scale forChildren—ThirdRevision38. Furthermore,
none of the children subjects was diagnosed with other developmental disorders
(for example, dysphasia, fragile X syndrome). Clinical diagnoses of HFA/
Asperger’s syndrome were confirmed by administering the ADI-R25 and the
ADOS32. Of the 58 participants with HFA/Asperger’s syndrome, 35 met the dia-
gnostic criteria forAsperger’s syndrome and 21met the diagnostic criteria forHFA
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according to ICD-10 (International Classification of Diseases v. 10) diagnostic
criteria39. Two participants met diagnostic criteria for PDD-NOS; these partici-
pants were excluded owing to theirmanifesting different and less severe symptoms
than our sample of children with HFA or Asperger’s syndrome.
Replication samples: Children’s Hospital Boston samples. Probands with a
documented history of clinical diagnosis of ASD were recruited at Children’s
Hospital Boston. To participate, they had to be over 24months of age and have at
least one biological parent or an affected sibling available. Subjects were excluded
if they had an underlying metabolic disorder or any chronic systemic disease, an
acquired developmental disability (for example, birth asphyxia, trauma-related
injury, meningitis, etc.), or cerebral palsy. All participants provided informed
consent and a phenotyping batterywas performed including theADOS, theADI-
R and other measures to assess cognitive status. Seventy-five per cent of subjects
with a clinical diagnosis met strict research criteria for ASD on both ADI-R and
ADOS. In addition, a complete family and medical history was obtained.
Replication samples: homozygosity mapping collaborative for autism
(HMCA) samples. Families with cousin marriages and children affected by
ASD with or without mental retardation were recruited by multiple collabora-
tors in the HMCA. The patients from Istanbul were evaluated by a child psychi-
atrist (N. M. Mukaddes) trained in the ADOS and ADI-R, and who made
diagnoses according to DSM-IV-TR criteria and the Childhood Autism Rating
Scale (CARS). Patients from Kuwait were enrolled from the Kuwait Centre for
Autism by S. Al-Saad. In Jeddah, Saudi Arabia, patients were evaluated by both a
developmental paediatrician (S. Balkhy) and a paediatric neurologist (G.
Gascon) and diagnoses were based on DSM-IV-TR criteria. In Lahore,
Pakistan, a neurologist (A. Hashmi) with training in the ADOS and ADI-R
diagnosed patients using DSM-IV-TR criteria. In most settings, patients were
enrolled from tertiary clinical centres and these patients had standard of care
neuromedical assessments, including physical examination, medical and neuro-
logical history, fragile X testing, and other genetic and metabolic testing when
indicated. MRI was obtained for patients in whom a brain malformation was
suspected or seizures were present. In addition, IQ scores (usually from the
Stanford–Binet) and adaptive behaviour measures were obtained from the
patients’ existing medical records. Secondary assessments were conducted on
the most informative pedigrees by the Boston clinical team in collaboration with
local multi-disciplinary teams. Clinical members of the Boston team included:
developmental psychologists (J. Ware, E. LeClaire, R. M. Joseph), paediatric
neurologists (G. H. Mochida, A. Poduri), a clinical geneticist (W.-H. Tan) and
a neuropsychiatrist (E. M. Morrow). The secondary assessment battery was
designed to obtain a comprehensive description of current and historical autism
symptomatology, cognitive and adaptive functioning, and neurological and
physical morphological status in the patient and pedigree. The secondary assess-
ment included: neurological examination; genetic dysmorphology examination;
the CARS; the Social Communication Questionnaire administered with probing
on par with the ADI-R by ADI-R reliable examiners; the ADOS (usually module
1); the Vineland Adaptive Behaviour Scales, second edition (VABS-II); Kaufman
Brief Intelligence Test, second edition (KBIT-II). ADOS assessments were video-
taped and dysmorphology findings were photographed for archival purposes.
Replication samples: AGP samples. Individuals typically received at least two of
three evaluations for autism symptoms: ADI-R, ADOS and clinical evaluation.
Of the 1,679 affected individuals from 1,443 families, 966 met criteria for autism
on the ADI-R and ADOS and most of these also had a clinical evaluation of
autism; 160 affected individuals met criteria for autism on one of the two dia-
gnostic instruments (ADI-R, ADOS) but were missing information on the other
instrument; and, 553 individuals met criteria for spectrum disorder on one or
both instruments. Affected individuals were recruited from both simplex and
multiplex families, 71%of this sample being frommultiplex families.Most of the
families were of European ancestry (83%).
Replication samples: Finnish autism family samples. Families were recruited
through university and central hospitals. Detailed clinical and medical examina-
tions were performed by experienced child neurologists as described elsewhere40.
Diagnoses were based on ICD-1039 and DSM-IV41 diagnostic nomenclatures.
Familieswithknownassociatedmedical conditionsor chromosomal abnormalities
were excluded from the study. A total of 106 families included 400 individuals for
whomgenotypedatawas available.Of these, 111 had a diagnosis of infantile autism
and13adiagnosis ofAsperger’s syndrome.All familieswere Finnish, except for one
family where the father was Turkish.
Replication samples: Iranian trio samples. Eligible participants in this study
were Iranian families with at least one child affected with ASD, including cases of
autistic disorder, Asperger’s syndrome and PDD-NOS. Eighty families (282
individuals) from Iran were ascertained and assessed. This sample was ascer-
tained by screening and diagnostic testing of over 90,000 preschool children
from Tehran in 2004. Diagnoses of children were made according to DSM-IV
criteria via the ADI-R and the ADOS. Patients with abnormal karyotypes and
dysmorphic features were excluded. Most of the families were father–mother–
child trios but some had more than one affected child. All affected biological
siblings were assessed with the same diagnostic tools. We have ascertained and
assessed 80 families (282 individuals) from Iran.
Affymetrix genotyping. The AGRE samples were genotyped on Affymetrix 5.0
chips at the Genetic Analysis Platform of the Broad Institute, using standard
protocols. The 5.0 chip was designed to genotype nearly 500,000 SNPs across the
genome to enable genome-wide association studies26,27. The NIMH controls
were genotyped at the Broad Institute using the Affymetrix 500K Sty and Nsp
chips, using a similar protocol6. The Autism Consortium and Montreal replica-
tion samples were also genotyped at the Broad Institute under the same condi-
tions. The NIMH autism samples were genotyped at the Johns Hopkins Center
for Complex Disease on the Affymetrix 500K (Nsp and Sty) and 5.0 platforms
using similar standard protocols.
Genotype calling for the 5.0 arrays was performed by Birdseed26,27 and for the
500K arrays was performed by BRLMM.As basicQC filters for the data generated
at the Broad Institute, we required that genotyping was.95% complete for each
individual, and that each family had fewer than 10,000 Mendelian inheritance
errors across the genome.We also required that each SNP had.95%genotyping,
fewer than 15 Mendelian errors, Hardy–Weinberg equilibrium P. 10210, and
minor allele frequency greater than 1%. For theAGRE sample, this left 2,883 high-
quality individuals genotyped for 399,147 SNPs with 99.6% average call rate. The
basic filters for the data generated at Johns Hopkins were individual call rates
.95% for 5.0 arrays and.90% for 500K arrays data, fewer than 5,000Mendelian
errors per family. Only monomorphic SNPs and those with greater than 50%
missing data were dropped, for 498,216 SNPs. Our combined data set had nearly
365,000 SNPs passing QC.
Sequenom genotyping. SNPs were assayed using Sequenom technology for the
AGP samples at three centres, namely Gulbenkian, Mt Sinai and Oxford: DNA
from 1,629 families representing numerous recruiting sites was genotyped for 54
SNPs. SNPs with .3% missing data, namely rs4690464, rs10513025, and
rs17088296, were excluded from analysis. The next step in our QC process was
to remove familieswith$4Mendelian errors, out of 51 remaining loci, under the
assumption that this indicated pedigree errors. Data from 110 families were
removed owing to Mendelian errors. Thereafter, SNPs were removed if they
showed excessive Mendelian errors (.16) in the remaining families. Using this
criterion, twomore SNPs, rs155437 and rs1925058, were removed from analysis.
It was apparent that DNA quality varied by study site and could be responsible
for concomitant genotype quality differences. Therefore, we also evaluated rate
of missing genotypes per locus and study site. Our analyses showed that DNA
from a few population samples showed excess missingness for two SNPs,
rs4742408 and rs7869239, relative to the remaining population samples.
Specifically three population samples showed more than 7% missing genotypes
for rs4742408 and rs7869239 whereas the remaining population samples had
about 1% or less missing genotypes. Therefore, for these loci we deleted geno-
types only from the samples showing excess missingness. As a final QC step, we
then evaluated missing genotypes for the remaining loci. If more than five loci
weremissing genotypes, the individual’s data was removed from analysis. By this
criterion 76 additional families became uninformative for family-based asso-
ciation analysis, leaving 1,443 families for association analysis. The Finnish
autism samples were genotyped in the Peltonen laboratory, and the Iranian trios
were genotyped at the Broad Institute using very similar protocols. All samples
were genotyped using aliquots from the same pooled primers and probes.
Copy number analysis. Because of previous reports of two large (.1 Mb),
independent de novo deletions spanning this locus42, we assessed the region
surrounding rs10513025 and the entire SEMA5A locus for copy number vari-
ation that could either explain or provide independent evidence of the import-
ance of this region to autism using Birdsuite26 to analyse all Affymetrix 5.0
samples. Birdsuite genotypes previously annotated common copy number poly-
morphisms27 and in parallel searches for novel copy number variants (CNVs)
using an HMM. Probe coverage in the region was good, with no 50-kb window
having fewer than 10 probes and an average spacing between probes of 2.5 kb,
allowing very good sensitivity for CNVs greater than 25 kb. We found no dele-
tions or duplications near this SNP, nor any overlapping the gene SEMA5A. The
closest CNS upstream and downstream of this SNP appeared to be a rare (,2–
3% frequency, previously annotated CNP) 40-kb deletion from 288 kb from the
39 end of SEMA5A, and a rare (,1% frequency, novel) 20-kb deletion 356 kb
upstream of the 59 end of SEMA5A. Each of these appeared to be segregating
polymorphisms, but fall far outside of the boundaries of SEMA5A and TAS2R1
and far beyond the linkage disequilibrium block containing rs10513025.
Expression analysis. Fresh-frozen brain tissue samples dissected from the cortex
(Brodmann area 19) were obtained through the Autism Tissue Program (http://
www.atpportal.org) from the Harvard Brain Bank and the NICHD Brain and
Tissue Bank at the University of Maryland from 20 samples with a primary
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diagnosis of autism, and 10 controls. Total RNA was extracted using TRIzol
reagent (Invitrogen) according to the manufacturer’s protocol. Complemen-
tary DNA (cDNA) was generated from 8mg of total RNA using the
Superscript III First-Strand Synthesis kit (Invitrogen). cDNA was diluted 1:5
in 10mM Tris and 1 ml of diluted cDNA was used per 10ml PCR reaction.
Quantitative real-time PCR was performed on a Lightcycler 480 (Roche
Applied Science) using 23 Taqman Gene Expression Master Mix and probes
obtained from Applied Biosystems (ABI): SEMA5A (Hs01549381_m1), MAP2
(Hs01103234_g1), TBP (Hs00920497_m1), GAPDH (4333764F). For multiplex
reactions, 0.5 ml FAM-labelled SEMA5A probe and 0.5ml VIC-labelled MAP2
probe were used per 10 ml reaction. The amount of SEMA5A relative to MAP2
was determined for each case using theDDCt method
43. Comparison of SEMA5A
toTBP andGAPDH yielded similar results. Logistic regressionwas performed on
autism status, adjusting for age at death, post-mortem interval, sex and SEMA5A
expression, with a 1-sided P-value reported for the association of lower SEMA5A
expression with autism status.
Determination of significance.Todetermine an appropriate experimental thresh-
old for genome-wide significance, permutation was performed on this data set by
gene-dropping, and genome-wide significance was estimated by taking the lowest
P-value from each of 1,000 permuted data sets and using the 50th as a threshold for
P, 0.05 experiment-wide significance (P, 2.53 1027). To calculate an estimate
of the effective number of tests (Teff),we used the following algorithm: (1) startwith
the most 59 SNP on a chromosome (SNPi,j), where i5 chromosome and j5 SNP
position, and calculate pairwise LD with all downstream SNPs within 1Mb
(r2[SNP1,13 SNP1,n]). (2) For SNP1,1, Teff(1,1)5 1-max(r
2[SNP1,1 x SNP1,n]). (3)
For chromosome i, Tef f (i)~
Xm
j~1
Teff (i,j), where m5 the total number of SNPs on
a chromosome. (4)Teff~
X23
i~1
Tef f (i). Because this algorithmonly accounts for pair-
wise LD, it provides a conservative estimate of the number of effective tests.
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